Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function

Design and Evaluation of TIM-3-CD28 Checkpoint Fusion Proteins to Improve Anti-CD19 CAR T-Cell Function

Therapeutic targeting of inhibitory checkpoint molecules in combination with chimeric antigen receptor (CAR) T cells is currently investigated in a variety of clinical studies for treatment of hematologic and solid malignancies. However, the impact of co-inhibitory axes and their therapeutic implica...

Full description

Bibliographic Details
Main Authors: Franziska Blaeschke, Eva Ortner, Dana Stenger, Jasmin Mahdawi, Antonia Apfelbeck, Nicola Habjan, Tanja Weißer, Theresa Kaeuferle, Semjon Willier, Sebastian Kobold, Tobias Feuchtinger
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Immunology
Subjects:
CAR T cells
checkpoint fusion proteins
pediatric leukemia
acute lymphoblastic leukemia (ALL)
TIM-3
CD19
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.845499/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.845499/full

Similar Items